The European Union Finances the Future of CAR-T Manufacturing

08/02/2016 - 3 minutes

CAR-T is the way forward in Cancer therapeutics, which is one of the leading causes of Mortality in the Western world. Now this European consortium has amassed €6M for a more unified approach to CAR-T under a European Union Commission program.

european_commission_carat_car-t_cancer_fundIn response to this major health issue Miltenyi Biotec (Germany) coordinates the new EU-funded project CARAT taking on the mission to deliver new methods to enable the wide use of novel personalised cancer treatment.

The project consortium comprises a multi-national team of leading experts from eight European partnering institutions, which include biotech and research centres in Germany, Italy, UK (and Wales) and France.


Equipped with a total budget of €6M, CARAT aims to integrate innovative cell manufacturing tools and enabling technologies into a new, comprehensive platform that will facilitate the safe, automated, and cost-efficient manufacture of highly effective so-called CAR T-cells.

Andrew Kaiser, scientific coordinator of the CARAT consortium at Miltenyi Biotec, explained that the goal of the program is to get CAR-T manufacturing process and research tools working together in order to overcome barriers to development through collaboration.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member